The highest risk was observed 8–14 and 15–28 days after initiating the SGLT2 inhibitor for UTI (IRR 1.49, 95% CI 1.07–2.08) and genital infections (IRR 2.11, 95% CI 1.66–2.67), respectively (17). This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.